Who Funds Sex Research and What They're Buying

The National Institutes of Health awarded approximately $31 billion in research grants in 2024. The portion of that budget allocated to the study of human sexual behavior, outside of HIV/STI prevention, was functionally a rounding error. The exact figure is difficult to calculate because NIH does not maintain a separate spending category for sex research; the studies that exist are scattered across institutes, folded into broader categories like reproductive health, behavioral science, and mental health. This organizational invisibility is not accidental. It is the funding equivalent of not making eye contact.

The NIH funds what Congress will defend, and Congress will defend what its constituents won’t use in attack ads. This means that the most politically sensitive research topics in the country are funded at levels determined not by scientific need but by political survivability. Cancer research gets $7 billion a year. Heart disease gets $4 billion. The entirety of human sexual behavior outside of disease prevention gets whatever can be tucked into a grant application that doesn’t use the word “sex” in the title.

The Federal Landscape Is Shaped by What Can’t Be Said Out Loud

The NIH funding cycle works like this: a researcher submits a grant proposal. The proposal goes through peer review. If the science is strong, it gets a priority score. The score determines whether it gets funded, based on the institute’s budget and the cutoff line that year. This system works reasonably well for most fields of science. For sex research, it contains a structural bias that operates before the first reviewer picks up the application.

The bias is in the framing requirement. A grant application to NIH must justify its significance in terms that the institute can defend to Congress. Research on erectile dysfunction justifies itself through prevalence data, quality-of-life metrics, and the economic burden of the condition. Research on female orgasm does not have the same ready-made justification framework, because the medical system has never classified the orgasm gap as a disease, a disorder, or a public health problem. The researcher studying female orgasm must frame her work as addressing “female sexual dysfunction” or “sexual health disparities” or “quality of life in reproductive-age women.” The framing is not false. But it determines what gets studied. If you can only get funding for dysfunction, you can only study dysfunction. The normal range of human sexual experience; pleasure, desire, satisfaction, variation; has no disease code, and NIH is in the business of funding disease research.

The political cycle amplifies this structural bias. Republican administrations have historically been more hostile to sex research funding than Democratic ones, but the difference is one of degree rather than kind. The Obama administration did not launch a national initiative on sexual behavior research. The Clinton administration funded abstinence-only programs alongside comprehensive sex education. The structural position of sex research at NIH is bipartisan in its marginality; neither party wants to be the one that expanded federal spending on studying what people do in bed.

The result is a funding landscape where the available conclusions are determined before the research is proposed. You can study sex if sex is a disease. You can study sex if sex transmits a disease. You can study sex if sex causes a problem that a drug might solve. You cannot study sex as a normal human behavior with variation, complexity, and intrinsic worth, because that framing has no champion in the appropriations process and no defense against the inevitable press release from a senator’s office asking why taxpayer money is being spent on orgasm research.

Pharma Bought the Questions It Wanted Answered

The pharmaceutical industry’s investment in sex research dwarfs the federal government’s, and the investment is precisely targeted. Pfizer’s development program for sildenafil, from initial research through FDA approval and post-marketing studies, cost an estimated $1 billion. The company earned that back within the first year of sales. The return on investment was so extraordinary that every major pharmaceutical company launched a sexual dysfunction program in Viagra’s wake, creating a research ecosystem that was lavishly funded, narrowly focused, and shaped entirely by the question of what could be turned into a drug.

Erectile dysfunction research received more pharmaceutical funding between 1998 and 2010 than all other areas of sex research combined. The funding went to mechanism studies, dose-response trials, formulation optimization, and expansion of the indication to younger men and to men with comorbidities. The research was good. The science was rigorous. The conclusions were useful. And the entire enterprise was organized around a single organ system in a single sex, because that’s where the commercial opportunity was.

The female sexual dysfunction market was the obvious next target, and the industry pursued it with the same logic it had applied to erectile dysfunction: define the condition, quantify the prevalence, develop the drug, market the diagnosis. The problem was that female sexual dysfunction, as a diagnostic category, was considerably more contested than erectile dysfunction. The definition kept shifting. Was it low desire? Difficulty with arousal? Inability to reach orgasm? Pain during intercourse? Each of these had different underlying mechanisms, different populations, and different intervention targets. The industry needed a unified diagnosis that could support a unified drug, and the science didn’t cooperate.

The attempt to create that unified diagnosis produced its own body of research, much of it industry-funded, much of it focused on establishing prevalence figures that would justify drug development. A widely cited 1999 study in JAMA, based on data from the National Health and Social Life Survey, reported that 43 percent of women experienced sexual dysfunction. The figure was derived by counting any sexual complaint; low desire, difficulty with arousal, pain, anxiety about performance; as a case of dysfunction, regardless of whether the woman herself considered it a problem. The 43 percent figure became the basis for pharmaceutical marketing materials and investor presentations. It also became the subject of sustained criticism from researchers who pointed out that turning every sexual complaint into a dysfunction was not medicine. It was market creation.

The industry-funded research was not fraudulent. It was directional. It asked the questions whose answers would support drug development and did not ask the questions whose answers would not. Why do some women have low desire? Is an interesting scientific question with many possible answers, most of them behavioral, relational, or contextual. Can this molecule increase the number of sexually satisfying events per month? is a commercially useful question with a testable answer. The industry funded the second kind of question and left the first kind to whoever else was willing to pay for it.

The Porn Industry Studies Itself, Badly

The pornography industry generates an estimated $15 billion annually in the United States. It has produced, over the decades, a body of self-funded research that is methodologically terrible and directionally interesting.

The industry’s research interests are commercial: what content drives engagement, what performers want to watch versus what they’ll pay for, how distribution platforms affect consumption patterns. The data exists in the form of internal analytics at companies like Pornhub (whose parent company, Aylo, publishes annual statistical reports on viewing patterns) and in market research conducted by industry trade groups. The data is not peer-reviewed. The methods are not published. The sample is users of specific platforms, not representative populations.

What the data shows, to the extent that it can be trusted, is that pornography consumption patterns are far more varied and less predictable than either the industry or its critics assume. The most-viewed categories shift by region, age, and platform. Women represent a larger share of pornography consumers than the public discourse acknowledges; roughly a third of Pornhub’s traffic, by the company’s own reporting. Search behavior reveals interests that don’t map onto the categories that dominate public debate; the most common searches are for specific performers, specific acts, and “realistic” or “authentic” content, not for the extreme or violent material that drives most of the political conversation about pornography.

None of this is rigorous enough to build scientific conclusions on. But it represents an enormous dataset about actual human sexual interest that academic researchers cannot access because the data is proprietary, the platforms are commercially motivated, and any researcher who proposed studying pornography consumption using industry data would face the same IRB and funding obstacles that have constrained sex research for decades.

The gap between what the porn industry knows about its consumers and what the scientific community knows about pornography’s effects is vast. The industry has behavioral data on billions of sessions. The scientific community has self-report surveys on thousands of respondents. The industry’s data is granular and unverifiable. The science is rigorous and underpowered. Neither side has what the other needs, and the political climate ensures they won’t share.

The Religious Right Funded the Conclusions It Wanted

Abstinence-only education was the single largest investment in sex research by ideologically motivated funders in American history, and the investment produced exactly the results the scientific method would predict: a body of research showing that the interventions didn’t work, followed by a political response that ignored the research and continued funding the interventions.

The Heritage Foundation, Focus on the Family, and allied organizations funded research programs throughout the 1990s and 2000s designed to demonstrate the effectiveness of abstinence-only education and the harms of premarital sex. The research was structured to support predetermined conclusions. Studies compared students who took virginity pledges with students who didn’t, without controlling for the religious and community environments that produced the pledge-takers in the first place. Studies measured attitudes rather than behavior, reporting that students who received abstinence education had more conservative attitudes about sex without measuring whether they actually had less sex. When behavioral data was collected, it consistently showed no difference in sexual activity between abstinence-educated and control groups, and these findings were either unpublished or buried in the supplementary materials.

The federally funded evaluations told the same story. The Title V abstinence programs, which received $50 million per year in dedicated federal funding starting in 1996, were subject to mandatory evaluation. The evaluations, conducted by independent research firms under congressional mandate, found no evidence that the programs reduced sexual activity, delayed sexual initiation, or reduced STI rates. The findings were published. The funding continued. The disconnect between the evidence and the policy was total and it lasted for over a decade.

The abstinence-only research apparatus served a function that had nothing to do with science. It provided a citation. When a senator needed to defend the appropriation, there were studies to point to. The studies didn’t show what the senator claimed they showed, but the existence of studies was sufficient. The research was a political product. Its purpose was to be cited, not to be read.

Independent Sex Research Survives in the Margins

The researchers who do rigorous, non-disease-framed sex research in 2026 operate in an economic environment that would be familiar to independent filmmakers or literary novelists. The funding comes from small foundations, European governments, and the occasional private donor. The Kinsey Institute at Indiana University, still the closest thing to a permanent home for sex research in the United States, operates on a budget that a mid-tier chemistry lab would find constraining. The Guttmacher Institute, which produces the most reliable data on reproductive behavior in America, is an independent nonprofit that receives no direct federal funding for its survey work.

Private foundations fill some of the gaps. The Ford Foundation and the MacArthur Foundation have funded sex research intermittently. The Hewlett Foundation supported reproductive health research for decades before shifting its focus. The funding is real but unstable; foundation priorities shift, program officers change, and a sex research grant that was fundable last year may not be fundable next year for reasons that have nothing to do with the science.

European funding agencies, particularly in the Netherlands, Germany, and the Scandinavian countries, support sex research at levels that American researchers find astonishing. The Dutch government funds population-level sex surveys on a regular cycle. The German Federal Centre for Health Education conducts longitudinal studies of sexual behavior and health. These programs operate in political environments where studying human sexuality is not treated as an inherently provocative act, and the data they produce is among the best in the world.

The result is that the most comprehensive data on human sexual behavior in 2026 comes from countries with populations smaller than many American states. The United States, which has the largest research infrastructure in the world, knows less about the sexual behavior of its own population than the Netherlands knows about its 17 million people. The knowledge gap is not a resource problem. It is a political problem. The resources exist. The will to deploy them does not.

Follow the money through any domain of sex research and you arrive at the same conclusion: the questions that get asked are the questions that someone is willing to pay for, and the willingness to pay is determined by politics, profit, and ideology, in that order. The science is the dependent variable. The funding is the independent variable. And the funding is never, ever independent.